Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Smithkline Beecham (SBH) -- Ignore unavailable to you. Want to Upgrade?

To: Mike Battin who wrote (34)	4/22/1998 1:05:00 PM
From: Henry Niman	Respond to of 61

SBH now says that they have no urge to merge. Interview linked to home.att.net

To: Mike Battin who wrote (34)	4/23/1998 7:11:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 61

Today's Financial Times has details on the SBH/GLX merger collapse. Details linked to the FT table linked to the SBH/GLX topic at home.att.net

To: Mike Battin who wrote (34)	6/5/1998 9:57:00 AM
From: Henry Niman	Respond to of 61

Did anyone here see Ligand's presentations a few months ago about a small molecule mimic of G-CSF (Neupogen)? The results were quite unexpected (a small molecule could bind to the G-CSF receptor and mimic its effect). Rumor has it that the data will be published in a week or two in Science and it will be a major event. When I heard about the data in February, I added a web page on it (at home.att.net ). The presented data was on a molecule that was mouse specific (recognized the mouse receptor but not the human one), but I suspect that LGND has a human version now (their pipeline time table at home.att.net indicates that a human version has been selected (under their hematopoietic growth factor alliance with SBH). Anyone have any more details?

To: Mike Battin who wrote (34)	6/5/1998 4:42:00 PM
From: Henry Niman	Respond to of 61

Here's the abstract: Discovery Of A Small Molecule G-Csf Mimic Jonathan I. Rosen, Ph.D., Senior Director, Transcription Research and New Leads Discovery, Ligand Pharmaceuticals, Inc. The JAK/STAT signal transduction pathway utilized by many cytokines can be exploited to develop high throughput screens for small molecule cytokine modulators. We applied this approach to the discovery of G-CSF mimics and have identified a non-peptidyl small molecule capable of activating granulocyte-colony stimulating factor (G-CSF) signal transduction pathways. This compound induces both the biochemical and cellular phenotypic responses characteristic of G-CSF. Remarkably, this compound is active in vivo with an efficacy similar to recombinant G-CSF. The identification of this compound provides proof of principle for drug discovery using JAK/STAT-based assays, and shows for the first time that a small non-peptidyl molecule can trigger the selective activation of a protein hormone receptor.

To: Mike Battin who wrote (34)	6/5/1998 5:30:00 PM
From: Henry Niman	Respond to of 61

I have updated the G-CSF page at home.att.net to include earlier discussions as well as some molecular info on the Neupogen mimic.

To: Mike Battin who wrote (34)	6/12/1998 7:09:00 AM
From: Henry Niman	Respond to of 61

Reuters is reporting on the merger rumor between SBH and GLX. However, Bloomberg has put out an SBH denial: paradise-web.com. Latest from CNBC is the SBH is up 4% and GLX is up 1% in London trading. I have linked stories to the merger table at home.att.net

To: Mike Battin who wrote (34)	6/14/1998 9:50:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 61

Talk of CEO departures for both SBH and GLX seem to be increasing. On Friday most stories centered on Leschly leaving SBH, but Saturday the Times of London suggested that analysts are now talking about both CEOs stepping aside. Stories are linked to the merger table at home.att.net